Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US. The company said the FDA would ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ... t expect major delays from here onwards and FDA should be able ...
The FDA’s decision ... The vaccine is being developed to prevent disease related to respiratory syncytial virus, or RSV ...
The FDA is working to conclude ... an investigational respiratory syncytial virus (RSV) vaccine, will be delayed due to ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to ... get its second product to market. The FDA hasn’t informed Moderna of any issues ...
The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA-1345, an investigational respiratory syncytial virus (RSV ...
The Cambridge company said the FDA cited “administrative constraints” in its decision to push ... on its review of the RSV vaccine. “Although regulatory delays are disappointing and usually ...
opens new tab respiratory syncytial virus (RSV) vaccine due to "administrative ... "We don't expect major delays from here onwards and FDA should be able to approve this by end of May," Jefferies ...